PALI — Palisade Bio Income Statement
0.000.00%
Last trade - 00:00- $3.48m
- -$6.26m
Annual income statement for Palisade Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.014 | 0 | 0 | 0.25 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 10.7 | 42.3 | 15.7 | 13.3 | 14.9 |
| Operating Profit | -10.7 | -42.3 | -15.7 | -13.1 | -14.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.3 | -26.6 | -14.3 | -12.3 | -14.4 |
| Net Income After Taxes | -16.3 | -26.6 | -14.3 | -12.3 | -14.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.3 | -26.6 | -14.3 | -12.3 | -14.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.3 | -26.6 | -14.3 | -12.3 | -14.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5,278 | 315 | -236 | -26.5 | -10.2 |